Loading...
XNASLRMR
Market cap233mUSD
Jan 10, Last price  
3.66USD
1D
-3.43%
1Q
-47.64%
Jan 2017
15.09%
IPO
-81.52%
Name

Larimar Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:LRMR chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
74.86%
Rev. gr., 5y
%
Revenues
0k
Net income
-37m
L+8.09%
-36,570,000-74,286,000-57,878,000-52,028,000-61,368,000-23,132,000-42,327,000-50,310,000-34,184,000-36,949,000
CFO
-33m
L+21.36%
-28,241,000-59,554,000-51,975,000-43,784,000-51,487,000-22,699,000-42,199,000-42,105,000-27,569,000-33,459,000
Earnings
Mar 12, 2025

Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
URL
https://larimartx.com/
IPO date
Jun 19, 2014
Employees
26
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
41,758
36,798
Unusual Expense (Income)
NOPBT
(41,758)
(36,798)
NOPBT Margin
Operating Taxes
(1,171)
Tax Rate
NOPAT
(41,758)
(35,627)
Net income
(36,949)
8.09%
(34,184)
-32.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
30
75,257
BB yield
-0.02%
-70.73%
Debt
Debt current
837
611
Long-term debt
10,255
10,205
Deferred revenue
Other long-term liabilities
Net debt
(77,037)
(108,951)
Cash flow
Cash from operating activities
(33,459)
(27,569)
CAPEX
(164)
(100)
Cash from investing activities
33,353
(90,960)
Cash from financing activities
30
75,257
FCF
(41,831)
(34,861)
Balance
Cash
86,790
118,428
Long term investments
1,339
1,339
Excess cash
88,129
119,767
Stockholders' equity
(188,430)
(151,593)
Invested Capital
275,696
267,904
ROIC
ROCE
EV
Common stock shares outstanding
43,901
25,761
Price
4.55
10.17%
4.13
-61.72%
Market cap
199,751
87.75%
106,395
-42.55%
EV
122,714
(2,556)
EBITDA
(41,447)
(36,480)
EV/EBITDA
0.07
Interest
318
Interest/NOPBT